SCHEMBL263858

SCHEMBL263858

CC(C)(c1ccc2cc(C(=O)NCc3ccnc4ccccc34)ccc2n1)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
EGLN1 Q9GZT9 1/20 0.41
ALDH1A1 P00352 2/20 0.41
PKM P14618 1/20 0.41
MAPT P10636 1/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.40
NAMPT P43490 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
DGAT2 Q96PD7 1/20 0.39
FLT1 P17948 1/20 0.39
KDR P35968 1/20 0.39
CA2 P00918 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
DDR1 Q08345 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263771 0.91 EGLN1 (0.40) SMN1; SMN2LMNAHTTADORA2AADORA1
SCHEMBL264812 0.91 TRPV1 (0.39) SMN1; SMN2LMNAHTTEGLN1ALDH1A1
SCHEMBL264386 0.88 SMN1; SMN2 (0.39) SMN1; SMN2LMNAHTTADORA2AADORA1
SCHEMBL263695 0.86 SMN1; SMN2 (0.57) SMN1; SMN2LMNAHTTALDH1A1PKM
SCHEMBL263302 0.84 EGLN1 (0.39) SMN1; SMN2LMNAHTTADORA2AADORA1
SCHEMBL265347 0.82 NAMPT (0.43) NAMPTDGAT2CA2TRPV1
SCHEMBL264363 0.81 PPARG (0.46) SMN1; SMN2LMNAALDH1A1GAATRPV1
SCHEMBL262685 0.81 PPARG (0.46) SMN1; SMN2LMNAALDH1A1GAATRPV1
SCHEMBL265243 0.81 TRPM8 (0.39)
SCHEMBL263915 0.81 TRPM8 (0.39) SMN1; SMN2LMNAALDH1A1GAATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US claimed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US claimed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 SMN1; SMN2 1166/4885LMNA 2567/4885HTT 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.